

Research Article

Effect of Verapamil on P-Glycoprotein Expression in Breast Carcinoma

Balakrishnan B, Dhandapani M,
Sivamani G*

PG & Research Department of Zoology and Biotechnology, A.V.V.M. Sri Pushpam College (Autonomous), Poondi, Thanjavur-613 503, Tamil Nadu, India

Date Received: 18th April 2018; Date accepted: 5th May 2018; Date Published: 16th May 2018

Abstract

Among Indian females, breast cancer has ranked number one cancer with mortality 12.7 per 100,000 women and age adjusted rate as high as 25.8 per 100,000 women. Statistics reports from various recent national cancer registries were compared for incidence, mortality rates. The age adjusted incidence rate of carcinoma of the breast was found as high as 41 per 100,000 women for Delhi, followed by Chennai (37.9), Bangalore (34.4) and Thiruvananthapuram District (33.7). One of the most common factor for the drug resistance in breast cancer is high expression of P-glycoprotein (P-gp) which is associated with a poor prognosis in patients. Consequently, P-gp represents a potential biomarker of drug resistance. However, a direct role of P-gp as a cause of clinical drug resistance has not been adequately tested in breast cancer. The objective of this study was to evaluate the effect of cyclophosphamide with and without verapamil on P-gp expression. Verapamil was found specific and effective against P-gp expression in breast cancer. In conclusion, treatment efficacy of cyclophos-

phamide is increased in combination with verapamil against most advanced breast cancer.

Keywords: P-Glycoprotein; Breast Carcinoma; Verapamil; Cyclophosphamide

INTRODUCTION

Worldwide, in female, breast cancer is the most common cancer representing closely 25% of all cancers with an estimated 1.67 million new cancer cases diagnosed in 2012. Women from rural areas have somewhat more number of cases (883,000) compared to developed (794,000) regions (1). Compared to United Kingdom (95 / 100,000) the age adjusted incidence rate of breast cancer is lower (25.8 / 100,000) in India but mortality is equivalence (17.1 vs 12.7 per 100,000) with United Kingdom (2). As described in global and Indian studies, there is a significant increase in the incidence and cancer associated morbidity and mortality in Indian subcontinent (3-7). In most countries, the prevalence of breast cancer is increasing, and it is highlighted that the incidence rate will escalate further in the next 20 years in spite of current efforts to prevent the disease (8-11). Risk factors involves in numbers of women with major breast cancer, including late age of first pregnancy, shorter or no periods of breastfeeding, later menopause, increase in obesity, alcohol consumption, inactivity, and hormone replacement therapy (11). There are many types of chemotherapy used to treat breast cancer. Common drugs include: Capecitabine, Carboplatin, Cisplatin, Cyclophosphamide, Docetaxel, Doxorubicin, etc.

MDR1 protein (P-gp) is a transmembrane glycoprotein with the molecular weight of 170-kDa transmembrane glycoprotein. This protein is encoded by the MDR1 (ABCB1) gene on the human chromosome 7p21. MDR1 protein overexpression has been associated with multidrug resistance in cancer cells including breast (12). The overexpression of this protein is reason for intrinsic and acquired drug resistance in different cancers (13). This overexpression can reduce intracellular anticancer-drug concentration as is frequently associated MDR in human cancer cells (14). Our knowledge is restricted on how these drugs interact with the MDR1 protein. The effects are different across cancer types. Breast

cancer is one of the most common cancers affecting more than one million individuals globally. Although, the chemoprevention is consequently one of the effective ways to cure breast cancer a major concern is potential of drug efflux transporter expression, which can significantly affect treatment efficacy. Here we hypothesized that down-regulation of MDR1 may enhance the effectiveness of chemotherapy. Recent studies demonstrated that verapamil is a calcium ion influx inhibitor and it is a well-known molecule developed against cancer chemo-resistant.

Materials and Methods

Monolayer culture

The MCF-7 breast carcinoma cell line was obtained directly from the ATCC (Manassas, VA, USA), and grown in RPMI (Thermo Fisher Scientific, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS, Sigma, St. Louis, MO) at 37°C in a 5% humidified CO₂ incubator. Characterization of cell line was done according to their surface expression phenotype. MCF-7 cell lines were grown for 48 hours with 80% confluency. After that the same cell lines were treated with Verapamil for 72 hours. These cells were used to form 3D tumorspheres along with controls. Verapamil and Cyclophosphamide was purchased from Selleckchem (USA).

Tumorsphere culture

Single cell suspensions were plated in 6-well tissue culture plates covered with poly-2 hydroxyethylmethacrylate (Sigma, St. Louis, MO) to prevent cell attachment, at a density of 1,000 cells/ml in serum free RPMI supplemented with 1% L-glutamine, 1% penicillin/streptomycin, 30% F12 (Sigma), 2% B27 (Thermo Fisher Scientific, Carlsbad, CA), 20 ng/ml recombinant human epidermal growth factor (EGF; Sigma, St. Louis, MO) and 20 ng/ml recombinant human fibroblast growth factor (FGF; Thermo Fisher Scientific, Carlsbad, CA). The medium was made semi-solid by the addition of 0.5% Methylcellulose (R&D Systems, Minneapolis, MN) to prevent cell aggregation. After 7 days in culture, 3D tumorspheres were collected by gentle centrifugation (200 x g) and dissociated enzymatically (5 min in 1:1 trypsin/RPMI solution at 37°C) and mechanically by passing through a 25G needle (6 strokes). Single cells were re-plated at a density.

Cell kinetic assay

MCF-7 cells were grown in a 96-well tissue cul-

ture plate with drugs and appropriate controls. Subsequently they were incubated with the WST-1 reagent (Dojindo Inc, Japan) for 4 hours. After this incubation period, the formazan dye formed was quantitated with a multi well spectrophotometer (ELISA reader). The measured absorbance directly correlates to the number of viable cells.

Cytotoxicity assay

To examine the effects of verapamil and cyclophosphamide in combination, MCF-7 cells cultured as monolayers or tumorspheres were treated with verapamil, cyclophosphamide for 3 days and cell death were measured with LDH cytotoxicity assay (Biovision, USA).

Flow cytometry

PerCP-conjugated CD44, BV711-conjugated CD24 monoclonal antibody was purchased from BD Bioscience. After 3 days of drug treatment the MCF-7 cells were dissociated with 0.25 % trypsin- EDTA (1 mM) (Invitrogen) for 3 min and washed with Calcium and magnesium free dulbecco phosphate buffered saline solution by spinning at 400g for 7 minutes. Then these cells were diluted in 100 µl FACS buffer (PBS containing 1 % fetal calf serum) and then incubated for 1 hr at 4° C in FACS buffer with the corresponding mAb: anti-CD44-PerCP, CD24-BV711. Flow cytometry analysis was performed with a BD FACS Caliber II flow cytometer (BD Biosciences).

Statistical Analysis

Data was expressed as mean standard deviation. Statistical packages for social sciences (SPSS) (SPSS UK Ltd, Woking, Surrey, UK) was used for data analysis. Chi-square analysis was used to assess significant changes between different groups. The level of significance was set at $P \leq 0.05$ and analysis of variance (one-way ANOVA) was used to compare the means of different groups.

Results

CPA promotes P-gp expression

We examined the expression of P-gp in MCF-7 cell line with or without CPA. We treated the MCF-7 cell line with CPA for 48 hrs and we checked the P-gp expression using flow cytometry. We noticed significant increase in P-gp expression when compared to the control. However, in control the expression of P-gp was unchanged.

Correlation between P-gp and CSC

We then thought to correlate the expression of P-gp with cancer stem cell markers (CD44+ and CD24-). For that we have treated the MCF-7 cell line with CPA for 2 days and we checked the expression of both P-gp and CD44+/CD24- using flow cytometry. We observed that in control arm, the expression of both P-gp and CD44+/CD24- were unchanged. However, in the CPA treated arm the expression of P-gp and CD44+/CD24- were significantly increased when compared untreated arm.

Targeting P-gp by using Verapamil

We confirmed that CPA alone is inducing the expression of P-gp and CSC in MCF-7 cell line. To suppress the expression of P-gp and CSC, we have chosen Verapamil (P-gp inhibitor). We have treated the MCF-7 cell line with and without verapamil for 48 hours and we have carried out the flow cytometry analysis from the verapamil

treated MCF-7 cell line. The flow cytometry data demonstrated that the MCF-7 cell line treated with verapamil has significant decrease in P-gp expression and also noticed decreased expression of CSC from the verapamil treated arm. But in the verapamil untreated arm, the expression of both P-gp and CD44+/CD24+ were unchanged in MCF-7 cell line.

Viability of MCF-7 Cell line in the presence of Verapamil (P-gp inhibitor)

After 3 days of verapamil treatment, MCF-7 cell lines were measured for the viability by WST-1 method. We observed very minimal or negligible difference between control and verapamil treated cell lines, and the same was observed in the morphological images under inverted microscope (data not shown here). This result indicates, verapamil alone play a vital role in suppressing the P-gp inhibitor and it did not affect the viability of the cells.




Fig 1: Increased level of CSC in CPA treated cells and in turn the expression of P-gp in MCF-7 cell lines.






Fig 2: CPA treated cells increases the CD44+/CD24- expression against control



Verapamil treated Day 9



Control Day 9

Fig 3: Verapamil treated cells fails to form 3D tumorosphere against untreated




Fig 4: Viability of CPA and CPA + Verapamil treated cells




Fig 5: Cytotoxicity of CPA Vs CPA+ Verapamil treated cells

Combination of Chemo with verapamil improves Cytotoxicity

We have got convincing data that verapamil alone has not affected the viability of MCF-7 cells. So, further we treated the MCF-7 cell line in combination with verapamil and CPA. Then we measured the cell death by LDH cytotoxicity assay. This experiment showed us that, combination of both P-gp inhibitor and chemotherapy drug drastically affect the viability of MCF-7 cell line.

Discussion

Like in most of the cancers, breast cancer also fails to respond to their current chemotherapies (9). The intrinsic and extrinsic resistance are contributed by P-glycoproteins. Here we set out to understand the relationship between the conventional chemotherapy (cyclophosphamide) and an inhibitor of transmembrane flux of calcium ions (verapamil). When combined with chemotherapeutic agent verapamil can help to promote intracellular drug accumulation. Treatment of cells along with P-gp inhibitor represents a potential strategy to improve the clinical outcomes.

Recent understanding of the drug resistance facilitated mechanisms underlying the treatment failures in breast cancer (13). Treating breast cancer using conventional chemotherapy along with P-gp inhibitor like verapamil increases the drug sensitiveness. In this context, verapamil decreases

P-glycoprotein and cancer stem cell expressions in MCF-7 cell lines. The same was shown in tumorspheres as well. When verapamil used the viability was not reduced, whereas when verapamil and CPA used combined the viability was drastically decreased. Deregulation of P-glycoprotein may be an important clinical and pathologic feature of breast cancer and a predictor of poor overall survival (12). In this study, we treated MCF-7 cell lines with verapamil, an inhibitor of p-glycoprotein that resulted in decreased levels of the stem cell markers CD44+/CD24-.

References

1. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; 136: E359– 86.
2. Gupta A, Shridhar K, Dhillon PK. A review of breast cancer awareness among women in India: cancer literate or awareness deficit? *Eur J Cancer* 2015; 51: 2058–66.
3. Porter PL. Global trends in breast cancer incidence and mortality. *Salud Publica de Mexico* 2009; 51: s141–s46.
4. Babu GR, Lakshmi SB, Thiyagarajan JA. Epidemiological correlates of breast cancer in South India. *Asian Pac J Cancer Prev* 2013; 14: 5077–83.

5. Ali I, Wani WA, Saleem K. Cancer scenario in India with future perspectives. *Cancer Therapy* 2011; 8: 56–70.
6. Srinath Reddy K, Shah B, Varghese C, Ramadoss A. Responding to the threat of chronic diseases in India. *Lancet* 2005; 366: 1744–9.
7. Balasubramaniam S, Rotti S, Vivekanandam S. Risk factors of female breast carcinoma: a case control study at Puducherry. *Indian J Cancer* 2013; 50: 65–70.
8. Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJ, Cox A, Curtin NJ, Dekker LV, Silva Idos S, Duffy SW, Easton DF, Eccles DM, Edwards DR, Edwards J, Evans D, Fenlon DF, Flanagan JM: Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. *Breast Cancer Res* 2013, 15: R92.
9. Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, Renehan AG, Forman D, Soerjomataram I: Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. *Eur J Cancer* 2013.
10. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM: Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res* 2014, 74:2913–2921.
11. Colditz GA, Bohlke K: Priorities for the primary prevention of breast cancer. *CA Cancer J Clin* 2014, 64:186–194.
12. Roberti A, La Sala D, Cinti C. Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. *J Cell Physiol*. 2006;207(3):571–81.
13. Pajic M, Iyer JK, Kersbergen A, van der Burg E, Nygren AO, Jonkers J, et al. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. *Cancer Res*. 2009;69(16):6396–404.
14. Liu ZH, He YP, Zhou Y, Zhang P, Qin H. Establishment and identification of the human multi-drug-resistant cholangiocarcinoma cell line QBC939/ADM. *Mol Biol Rep*. 2011;38(5):3075–82.